Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab in Pediatric Patients With Refractory Juvenile Rheumatoid Arthritis
NCT00029042Phase 2Terminated
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Start
- Jan 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of infliximab in juvenile idiopathic arthritis (JIA) (2 arms), sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases. Primary endpoint: 70% Clinical Response at 62 weeks. Started Jan 2002; status: terminated.
02
Drugs
infliximab
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT00029042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00029042.